EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Is radical local therapy effective in postoperative recurrent EGFR ‐mutated non‐small cell lung cancer?

Tomoyoshi Takenaka iD, Tokujiro Yano, Koji Yamazaki iD, Tatsuro Okamoto, Motoharu Hamatake, Shinkichi Takamori iD, Mikihiro Kohno, Naoko Miura, Mototsugu Shimokawa, Tomoharu Yoshizumi, Kyushu University Lung Surgery Study Group

Thoracic Cancer · 2023

DOI: 10.1111/1759-7714.14911 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Thoracic Cancer, 2023. Verfasst von Tomoyoshi Takenaka und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Long‐term survival can be achieved with radical local therapy in some cases of postoperative recurrence of non‐small cell lung cancer (NSCLC). Here, we evaluated post‐recurrence survival (PRS) after treatment of postoperative recurrent epidermal growth factor receptor ( EGFR ) mutated NSCLC and examined the effectiveness of radical local therapy.

Methods

This multicenter prospective cohort study was conducted in 14 hospitals. The inclusion criteria for this study were patients with recurrence after radical resection for NSCLC. Information about the patient characteristics at recurrence, tumor‐related variables, primary surgery, and treatment for recurrence was collected. After registration, follow‐up data (e.g., treatment and survival outcomes) were obtained and analyzed.

Results

From 2010 to 2015, 505 patients with recurrent NSCLC were enrolled into the study, and 154 EGFR mutation‐positive cases were included. As the initial treatment for recurrence, 111 patients (72%) received chemotherapy, 14 (9%) received chemoradiotherapy, 14 (9%) received definitive radiotherapy, and seven (5%) received surgical resection. The remaining eight patients (5%) received supportive care. The median PRS and 5‐year survival rates for all cases were 64 months and 53.2%, respectively. The 5‐year survival rate according to the initial treatment was as follows: supportive care, 0%; chemotherapy, 53.3% and radical local therapy, 60.1%. The six patients who received radical local treatment remained recurrence‐free for more than 3 years after recurrence with only initial treatment.

Conclusions

Although radical local therapy may be curative in some patients, chemotherapy including EGFR‐TKI treatment is expected to provide long‐term survival comparable to that of radical local therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsHumansProspective StudiesNeoplasm Recurrence, LocalErbB ReceptorsMutationRetrospective StudiesProtein Kinase Inhibitors

Stichwörter der Autor:innen

epidermal growth factor receptor mutationnon-small cell lung cancerpost-recurrence survivalrecurrencesurgical resection

Substanzen

ErbB ReceptorsProtein Kinase InhibitorsEGFR protein, human

Autor:innen und Institutionen

  • Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Department of General Thoracic Surgery, National Hospital Organization, Beppu Medical Center, Beppu, Japan.
  • Department of Thoracic Surgery and Clinical Research Institute, National Hospital Organization, Kyushu Medical Center, Fukuoka, Japan.
  • Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Japan.
  • Department of Thoracic Surgery, Kitakyushu Municipal Medical Center, Kitakyushu, Japan.
  • Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Ube, Japan.

ORCID-Profile: Tomoyoshi Takenaka, Koji Yamazaki, Shinkichi Takamori

Zitieren

APA

Takenaka, T., Yano, T., Yamazaki, K., Okamoto, T., Hamatake, M., Takamori, S., Kohno, M., Miura, N., Shimokawa, M., Yoshizumi, T., & Kyushu University Lung Surgery Study Group (2023). Is radical local therapy effective in postoperative recurrent EGFR ‐mutated non‐small cell lung cancer?. Thoracic Cancer. https://doi.org/10.1111/1759-7714.14911

Vancouver

Takenaka T, Yano T, Yamazaki K, Okamoto T, Hamatake M, Takamori S, et al. Is radical local therapy effective in postoperative recurrent EGFR ‐mutated non‐small cell lung cancer?. Thoracic Cancer. 2023. doi:10.1111/1759-7714.14911

BibTeX
@article{Takenaka2023,
  author = {Takenaka, Tomoyoshi and Yano, Tokujiro and Yamazaki, Koji and Okamoto, Tatsuro and Hamatake, Motoharu and Takamori, Shinkichi and Kohno, Mikihiro and Miura, Naoko and Shimokawa, Mototsugu and Yoshizumi, Tomoharu and Kyushu University Lung Surgery Study Group, Kyushu University Lung Surgery Study Group},
  title = {Is radical local therapy effective in postoperative recurrent EGFR ‐mutated non‐small cell lung cancer?},
  journal = {Thoracic Cancer},
  year = {2023},
  doi = {10.1111/1759-7714.14911}
}
Kostenlos starten →